Drug Profile
Research programme: kinase inhibitors - Evotec SE/Nycomed
Latest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Nycomed
- Developer Nycomed
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 02 Apr 2008 Preclinical development is ongoing
- 12 Oct 2004 Preclinical trials in Undefined in Germany (unspecified route)